STOCK TITAN

Cumberland Pharmaceuticals Inc Stock Price, News & Analysis

CPIX Nasdaq

Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) provides specialty pharmaceutical solutions for critical care and underserved medical needs. This news hub offers investors and healthcare professionals verified updates on the company's FDA-approved therapies, clinical developments, and strategic initiatives.

Access timely reports on product approvals, clinical trial milestones, and corporate partnerships across Cumberland's core therapeutic areas: hospital acute care, oncology support, gastroenterology treatments, and rare disease therapies. Our curated news collection enables informed decision-making through coverage of financial results, regulatory submissions, and market expansion efforts.

Key updates include developments for Cumberland's Ifetroban clinical program targeting rare conditions, international distribution agreements, and innovations in pain management solutions like Caldolor®. All content undergoes strict verification to ensure accuracy and relevance for stakeholders.

Bookmark this page for centralized access to CPIX's latest pharmaceutical advancements and corporate announcements. Check regularly for essential updates impacting the specialty medicine sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
Rhea-AI Summary

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a 17% increase in net revenues for 2022, totaling $42 million, and achieved $8 million in cash flow. The company acquired Sancuso®, enhancing its oncology product lineup. In Q4 2022, net revenues reached $9.1 million, with Sancuso® contributing $2.4 million. Operating expenses were $47.7 million, up from $43.7 million in 2021. Cumberland moved its headquarters to Nashville, supporting growth and collaboration with Vanderbilt University. The company continues ongoing clinical development for ifetroban in severe diseases, while partnerships for international product launches signify growth potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none

FAQ

What is the current stock price of Cumberland Pharmaceuticals (CPIX)?

The current stock price of Cumberland Pharmaceuticals (CPIX) is $4.7 as of May 9, 2025.

What is the market cap of Cumberland Pharmaceuticals (CPIX)?

The market cap of Cumberland Pharmaceuticals (CPIX) is approximately 62.9M.
Cumberland Pharmaceuticals Inc

Nasdaq:CPIX

CPIX Rankings

CPIX Stock Data

62.86M
8.75M
44.47%
22.13%
2.25%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE,